Active pharmaceuticals often find their way to the world’s drinking water, though the consequences of this are largely unknown. Now, new research published yesterday (June 6) in PLoS ONE, identifies at least one possible outcome—altered gene expression. Fathead minnows exposed to psychoactive medications in the water showed gene expression profiles that are associated with autism spectrum disorder in humans. The results suggest a potential environmental trigger for autism spectrum disorders (ASD) in genetically susceptible populations, and may explain the association between antidepressant use by pregnant women and ASD in their kids.Michael Thomas of Idaho State University and colleagues tested three psychoactive pharmaceuticals—fluoxetine, a selective serotonin reuptake inhibitor (SSRI); venlafaxine, a serotonin-norepinephrine reuptake inhibitor; and carbamazepine, used to control seizures. They used concentrations estimated to be the highest found in the environment, which are still quite low, and saw that fish exhibited altered expression patterns in their brains...

“Our findings suggest a new potential trigger for idiopathic autism in genetically susceptible individuals involving an overlooked source of environmental contamination,” the authors wrote.

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?